Trial · NCT02964572
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
NCT02964572, Not applicable, Completed, Yonsei University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes. Trials, record NCT02964572. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02964572
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
- NCT number
- NCT02964572
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 61 participants, actual
- Lead sponsor
- Yonsei University
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- Glimepiride, Empagliflozin
- First posted
- 2016-11-16
- Last updated
- 2020-08-27
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | changes in the secretion of IL-1 beta from peripheral blood mononuclear cells | Day 60 | The effect of empagliflozin on the secretion of IL-1beta from peripheral blood mononuclear cells |
| Secondary | Changes in the secretion of TNF-alpha from peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of beta-hydroxybutyrate, before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in body weight (kg), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of insulin (µU/mL), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of glucagon (pg/mL), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of free fatty acid (μEq/L), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum glycated albumin (%), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of glucose (mg/dL), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of uric acid (mg/dL), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35572519 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02964572
GET https://conductscience.org/api/trials/v1/NCT02964572/registered